Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27018597 | 0.85 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL27018593 | 0.82 | SPHK1 (0.43) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL27018596 | 0.79 | SPHK1 (0.41) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL8442635 | 0.74 | SPHK1 (0.50) | SPHK1CTSKBRD4MEN1ALDH1A1 | |
| SCHEMBL24072941 | 0.72 | SPHK1 (0.46) | SPHK1CTSKBRD4MEN1ALDH1A1 | |
| SCHEMBL29323054 | 0.72 | SPHK1 (0.46) | SPHK1CTSKBRD4MEN1ALDH1A1 | |
| SCHEMBL31072538 | 0.72 | SPHK1 (0.46) | SPHK1CTSKBRD4MEN1ALDH1A1 | |
| SCHEMBL3465671 | 0.72 | SPHK1 (0.46) | SPHK1CTSKBRD4MEN1ALDH1A1 | |
| SCHEMBL3465669 | 0.72 | SPHK1 (0.46) | SPHK1CTSKBRD4MEN1ALDH1A1 | |
| SCHEMBL31526652 | 0.72 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | SPHK1 2072/4885CTSK 918/4885BRD4 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.